New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
Boston Scientific, an MD+DI Medtech Company of the Year finalist, announced positive three-year primary endpoint results over the weekend from the OPTION global clinical trial of its Watchman Flx left ...
Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
Boston Scientific has secured label expansion from FDA for its Watchman FLX and Watchman FLX Pro. The Marlborough, MA-based company had already expected the label expansion, which now includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results